as 05-30-2025 4:00pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | WASHINGTON |
Market Cap: | 237.9M | IPO Year: | 2006 |
Target Price: | $15.33 | AVG Volume (30 days): | 519.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.76 | EPS Growth: | N/A |
52 Week Low/High: | $3.81 - $6.75 | Next Earning Date: | 05-07-2025 |
Revenue: | $201,351,000 | Revenue Growth: | 13.37% |
Revenue Growth (this year): | 16.86% | Revenue Growth (next year): | 39.78% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Polymeropoulos Mihael Hristos | VNDA | President and CEO | May 16 '25 | Buy | $4.22 | 20,000 | $84,472.00 | 2,315,731 | |
Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 6 '25 | Buy | $5.02 | 10,000 | $50,150.00 | 2,315,731 | |
Polymeropoulos Mihael Hristos | VNDA | President and CEO | Mar 5 '25 | Buy | $5.02 | 10,000 | $50,200.00 | 2,315,731 |
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Argus Research
11 days ago
Argus Research
16 days ago
Argus Research
17 days ago
Argus Research
18 days ago
Argus Research
23 days ago
Thomson Reuters StreetEvents
24 days ago
Argus Research
24 days ago
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.